Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: monoclonal antibodies - Jinghua Pharmaceutical/Kadmon Corporation

Next Previous
Search
Drug Profile

Research programme: monoclonal antibodies - Jinghua Pharmaceutical/Kadmon Corporation

Alternative Names: Anti-VEGFR2 and anti-PD-L1 monoclonal antibodies - Jinghua/Kadmon; KD-035; KD-036

Latest Information Update: 20 Apr 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kadmon Corporation
  • Developer Jinghua Pharmaceutical; Kadmon Corporation
  • Class Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 31 Dec 2019 Kadmon Holdings has patents protection for KD 035 in the US, China, Europe, Japan, Eurasia
  • 28 Dec 2019 No recent reports of development identified for research development in Cancer in China (Parenteral)
  • 20 Nov 2015 Fully human anti-VEGFR 2 and anti-PD L1 monoclonal antibodies licensed to Jinghua Pharmaceutical in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top